Market Overview

Altasciences to Acquire Preclinical Safety Testing Services


Altasciences announced today that it has signed a definitive agreement
to acquire the preclinical testing business of SNBL U.S.A. The
transaction is expected to be completed at the end of September. This
acquisition will add comprehensive preclinical safety testing services
to Altasciences' current full-service clinical and bioanalytical
offerings. Altasciences will now support all crucial steps in
early-stage drug development, from lead candidate selection to proof of
concept. This acquisition is an integral part of the company's strategic
growth plan to address the ever-changing outsourcing challenges of
biopharmaceutical companies across the globe.

"Expanding our services to include preclinical safety testing was a
natural progression for Altasciences and the perfect complement to our
current offering. With the extensive preclinical and clinical experience
of our management and scientific teams, we knew we had a unique
opportunity to work towards creating a strategic combination of services
that would make the outsourcing process for our clients easier and more
cost effective, while shortening the timeline to proof of concept,"
Chris Perkin, Chief Executive Officer of Altasciences.

Transferring data, projects and/or methodologies between CROs, or
between different groups within a multi-service CRO, can take time, is
prone to error, and can lead to prolonged R&D timelines. Altasciences is
looking to address these challenges through the integration of strategic
acquisitions, such as the SNBL U.S.A. preclinical business. The result
will be a fully integrated offering, improving ‘speed and ease'
throughout early stage development by carrying best practices across
services along with the addition of platforms that support integrated
data capture and program management, allowing for quicker, more
proactive development timeline adjustments and decision making to
improve R&D efficiency for biopharmaceutical customers.

"Our customers have told us that they see value in carrying learnings
from preclinical studies through to trial design decisions in the early
phases of clinical development. Our strength in Phase I trial conduct
and support, our extensive bioanalytical capabilities and our track
record of customer service are the perfect foundation for adding
preclinical safety testing capabilities,"
added Chris Perkin.

About Altasciences

is a mid-size contract research organization that encompasses Algorithme
in Montreal, QC, Vince
& Associates Clinical Research
in Overland Park, KS, and Algorithme
Pharma USA
in Fargo, ND, with an overall company focus on supporting
early-stage drug development. With over 25 years of industry experience,
Altasciences provides clinical services to an international customer
base of biopharmaceutical companies. Altasciences' full-service
solutions offering in this critical stage of drug development includes
clinical pharmacology, medical writing, biostatistics, data management
and bioanalysis.

View Comments and Join the Discussion!